Livi®, the First FDA-Cleared After-Sex Absorption Device, Is Now Available
Doctor-created Livi addresses a long-overlooked need in post-sex intimate health, available exclusively at MyLivi.com.
Created to address a common yet rarely discussed aspect of women's intimate health, Livi offers a simple, discreet solution for managing post-sex fluids that can contribute to lingering discharge and odor, including those associated with temporary pH changes following semen exposure.
Founded by former Pfizer innovation executive
The company's progress has been supported by anchor investor Atlantic Health whose partnership has supplied valuable financial and research resources, enabling LiviWell to advance through critical development milestones and regulatory submission.
"For far too long, women have been expected to simply accept common post-sex symptoms like odor and discharge," said Dawn Halkuff, Chief Executive Officer of LiviWell. "Bringing these everyday realities into the conversation is an important part of advancing women's intimate health."
Co-Founder
Livi was co-developed with Dr.
Livi is inserted vaginally using a familiar tampon-style applicator to absorb semen and other vaginal discharge after intercourse before being removed and discarded. The product is intended for single use and should be used according to the Instructions for Use.
Livi is available beginning
About LiviWell
LiviWell is a women's health company based in Mountain Lakes, New Jersey, dedicated to developing innovative solutions for women's intimate health and wellness. The company combines cutting-edge technology with rigorous clinical validation to bring transformative products to market. For more information, visit www.MyLivi.com.
Media Contact
Jess Woolridge | [email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/livi-the-first-fda-cleared-after-sex-absorption-device-is-now-available-302853329.html
SOURCE LiviWell
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lundbeckfond Invest A/S launches voluntary exchange offer for A-shares in H. Lundbeck A/S
- FLSmidth H1 2026 Interim Financial Report: Continued strong order growth and higher revenue conversion support full-year guidance adjustment
- Primax Tymphany Group Advances Intelligent Robotics and Automation with AI Sensor Fusion at Automation Taipei 2026
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share